A Phase 2, Randomized, Dose-Response Trial of Taprenepag Isopropyl (PF-04217329) Versus Latanoprost 0.005% in Open-Angle Glaucoma and Ocular Hypertension

Author: Schachar Ronald A.   Raber Susan   Courtney Rachel   Zhang Min  

Publisher: Informa Healthcare

ISSN: 0271-3683

Source: Current Eye Research, Vol.36, Iss.9, 2011-09, pp. : 809-817

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract